|
1
|
Ariel A, Maridonneau-Parini I,
Rovere-Querini P, Levine JS and Mühl H: Macrophages in inflammation
and its resolution. Front Immunol. 3:2–3. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu YC, Zou XB, Chai YF and Yao YM:
Macrophage polarization in inflammatory diseases. Int J Biol Sci.
10:520–529. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murray PJ: Macrophage polarization. Annu
Rev Physiol. 79:541–566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roszer T: Understanding the mysterious M2
macrophage through activation markers and effector mechanisms.
Mediators Inflamm. 2015:16–18. 2015. View Article : Google Scholar
|
|
5
|
Kurowska-Stolarska M and Alivernini S:
Synovial tissue macrophages: Friend or foe? RMD Open.
3:e0005272017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Müller S, Kohanbash G, Liu SJ, Alvarado B,
Carrera D, Bhaduri A, Watchmaker PB, Yagnik G, Di Lullo E,
Malatesta M, et al: Single-cell profiling of human gliomas reveals
macrophage ontogeny as a basis for regional differences in
macrophage activation in the tumor microenvironment. Genome Biol.
18:2342017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hambardzumyan D, Gutmann DH and Kettenmann
H: The role of microglia and macrophages in glioma maintenance and
progression. Nat Neurosci. 19:20–27. 2015. View Article : Google Scholar
|
|
8
|
Rhee I: Diverse macrophages polarization
in tumor microenvironment. Arch Pharm Res. 39:1588–1596. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan R, Li S, Geng H, Wang X, Guan Q, Li
X, Ren C and Yuan X: Reversing the polarization of tumor-associated
macrophages inhibits tumor metastasis. Int Immunopharmacol.
49:30–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanwar MK, Gilbert MR and Holland EC: Gene
expression microarray analysis reveals YKL-40 to be a potential
serum marker for malignant character in human glioma. Cancer Res.
62:4364–4368. 2002.PubMed/NCBI
|
|
11
|
Biggar RJ, Johansen JS, Smedby KE,
Rostgaard K, Chang ET, Adami HO, Glimelius B, Molin D,
Hamilton-Dutoit S, Melbye M and Hjalgrim H: Serum YKL-40 and
interleukin 6 levels in Hodgkin lymphoma. Clin Cancer Res.
14:6974–6978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schmidt H, Johansen JS, Gehl J, Geertsen
PF, Fode K and von der Maase H: Elevated serum level of YKL-40 is
an independent prognostic factor for poor survival in patients with
metastatic melanoma. Cancer. 106:1130–1139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamura Y, Kato H, Oh A, Kisanuki K,
Tsuchiya S, Terashima G and Shimasaki Y: Glioblastoma and other
malignant gliomas a clinical review. JAMA. 310:1842–1850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 world health organization
classification of tumors of the central nervous system: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hung CH, Chen FM, Lin YC, Tsai ML, Wang
SL, Chen YC, Chen YT and Hou MF: Altered monocyte differentiation
and macrophage polarization patterns in patients with breast
cancer. BMC Cancer. 18:3662018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tu J, Cheung HH, Lu G, Chen Z and Chan WY:
MicroRNA-10a promotes granulosa cells tumor development via
PTEN-AKT/Wnt regulatory axis. Cell Death Dis. 9:10762018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nutt CL, Betensky RA, Brower MA, Batchelor
TT, Louis DN and Stemmer-Rachamimov AO: YKL-40 is a differential
diagnostic marker for histologic subtypes of high-grade gliomas.
Clin Cancer Res. 11:2258–2264. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hormigo A, Gu B, Karimi S, Riedel E,
Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM
and Holland EC: YKL-40 and matrix metalloproteinase-9 as potential
serum biomarkers for patients with high-grade gliomas. Clin Cancer
Res. 12:5698–5704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ku BM, Lee YK, Ryu J, Jeong JY, Choi J,
Eun KM, Shin HY, Kim DG, Hwang EM, Yoo JC, et al: CHI3L1 (YKL-40)
is expressed in human gliomas and regulates the invasion, growth
and survival of glioma cells. Int J Cancer. 128:1316–1326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ludwig K and Kornblum HI: Molecular
markers in glioma. J Neurooncol. 134:505–512. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agnihotri S, Burrell KE, Wolf A, Jalali S,
Hawkins C, Rutka JT and Zadeh G: Glioblastoma, a brief review of
history, molecular genetics, animal models and novel therapeutic
strategies. Arch Immunol Ther Exp (Warsz). 61:25–41. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iwamoto FM, Hottinger AF, Karimi S, Riedel
E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher
M, et al: Serum YKL-40 is a marker of prognosis and disease status
in high-grade gliomas. Neuro Oncol. 13:1244–1251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao YH, Pan ZY, Wang ZF, Ma C, Weng H and
Li ZQ: YKL-40 in high-grade glioma: Prognostic value of protein
versus mRNA expression. Glioma. 1:104–110. 2018. View Article : Google Scholar
|
|
24
|
Ostuni R, Kratochvill F, Murray PJ and
Natoli G: Macrophages and cancer: From mechanisms to therapeutic
implications. Trends Immunol. 36:229–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng H, Wang Z, Fu L and Xu T: Macrophage
polarization in the development and progression of ovarian cancers:
An overview. Front Oncol. 9:4212019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Martinez FO, Sica A, Mantovani A and
Locati M: Macrophage activation and polarization. Bioscience.
13:453–461. 2008.
|
|
28
|
Shao R: YKL-40 acts as an angiogenic
factor to promote tumor angiogenesis. Front Physiol. 4:1222013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horbinski C, Wang G and Wiley CA: YKL-40
is directly produced by tumor cells and is inversely linked to EGFR
in glioblastomas. Int J Clin Exp Pathol. 3:226–237. 2010.PubMed/NCBI
|
|
30
|
Ricard C, Tchoghandjian A, Luche H, Grenot
P, Figarella-Branger D, Rougon G, Malissen M and Debarbieux F:
Phenotypic dynamics of microglial and monocyte-derived cells in
glioblastoma-bearing mice. Sci Rep. 6:263812016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Di Rosa M, Tibullo D, Saccone S, Distefano
G, Basile MS, Di Raimondo F and Malaguarnera L: CHI3L1 nuclear
localization in monocyte derived dendritic cells. Immunobiology.
221:347–356. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Y, Du W, Chen Z and Xiang C:
Upregulation of PD-L1 by SPP1 mediates macrophage polarization and
facilitates immune escape in lung adenocarcinoma. Exp Cell Res.
359:449–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
